Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells

Oncology

Volumn 70, Issue 6, 2007, Pages 483-492

  Alagbala, Adebusola A ^a   Johnson, Candace S ^a   Trump, Donald L ^a   Posner, Gary H ^b   Foster, Barbara A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; Calcitriol; Molecular response; Paricalcitol; QW 1624F2 2; Squamous cell carcinoma cells; Vitamin D; Vitamin D analogs

Indexed keywords

1ALPHA HYDROXYMETHYL 16 ENE 24,24 DIFLUORO 25 HYDROXY 26,27 BIS HOMOVITAMIN D3; CASPASE 3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PARICALCITOL; PROTEIN KINASE B; QW 1624F2 2; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BROMODEOXYURIDINE; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; ERGOCALCIFEROLS; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C3H; MITOGEN-ACTIVATED PROTEIN KINASE 3; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33847343428     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098813     Document Type: Article

References (53)

1. Holick MF: The photobiology of vitamin D3 in man; in Kuman R (ed): Vitamin D: Basic and Clinical Aspects. Boston, Martinus Nijhoff, 1984, pp 197-216.
2. Bikle DD, Pillai S: Vitamin D, calcium, and epidermal differentiation. Endocr Rev 1993;14:3-19.
3. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 1998;240:889-895.
4. Christakos S, Raval-Pandya M, Wernyj RP, Yang W: Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 1996;316:361-371.
5. Johnson CS, Hershberger PA, Trump DL: Vitamin D-related therapies in prostate cancer. Cancer Metastasis Rev 2002;21:147-158.
6. Getzenberg R, Light B, Lapco P, Konety B, Nangia A, Acierno J, Dhir R, Shurin Z, Day R, Trump D, Johnson C: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
7. Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44:693-702.
8. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR: 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712-3718.
9. McElwain MC, Dettelbach MA, Modzelewski RA, Russell DM, Uskokovic MR, Smith DC, Trump DL, Johnson CS: Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system. Mol Cell Differ 1995;3:31-50.
10. Shternfeld IS, Lasudry JG, Chappell RJ, Darjatmoko SR, Albert DM: Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Arch Ophthalmol 1996;114:1396-1401.
11. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG: Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 1997;76:1017-1020.
12. Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996;56:264-267.
13. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-153.
14. Zhuang SH, Burnstein KL: Antiproliferative effect of 1alpha,25- dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-1207.
15. Sheikh MS, Rochefort H, Garcia M: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995;11:1899-1905.
16. Light B, Yu W, McElwain M, Russell D, Trump D, Johnson C: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-3764.
17. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS: 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-2649.
18. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
19. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
20. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58:367-376.
21. Welsh J, VanWeelden K, Flanagan L, Byrne I, Nolan E, Narvaez CJ: The role of vitamin D3 and antiestrogens in modulating apoptosis of breast cancer cells and tumors. Subcell Biochem 1998;30:245-270.
22. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304-2312.
23. Modzelewski R, Hershberger P, Johnson C, Trump D: Apoptotic effects of paclitaxel and calcitriol in rat Dunning MLL and human PC-3 prostate tumor cells in vitro. Proc Am Assoc Cancer Res 1999;40:580a.
24. McGuire TF, Trump DL, Johnson CS: Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276:26365-26373.
25. Beer TM, Munar M, Henner WD: A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001;91:2431-2439.
26. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL: Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72:648-659.
27. Cunningham D, Gilchrist N, Cowan R, Forrest G, McArdle C, Soukop M: Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Br Med J 1985;291:1153-1155.
28. French LE, Ramelet AA, Saurat JH: Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. Lancet 1994;344:686-687.
29. Osborne JL, Schwartz GG, Smith DC, Bahnson R, Day RS, Trump DL: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-198.
30. Gross C, Stamey T, Hancock S, Feldman D: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:2035-2040.
31. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS: Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106:2136-2142.
32. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta G, Ruether JD, Henner WMD, Chi KN, Cruickshank S; ASCENT Investigators: Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Int J Clin Oncol, June 2005, p 4516.
33. Beer TM, Lemmon D, Lowe BA, Henner WD: High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003;97:1217-1224.
34. Chen TC, Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003;14:423-430.
35. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432.
36. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25- dihydroxyvitamin D2. Am J Kidney Dis 1998;32:S48-54.
37. Kumagai T, O'Kelly J, Said JW, Koeffler HP: Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003;95:896-905.
38. Molnar I, Kute T, Willingham MC, Schwartz GG: 19-Nor-1alpha,25- dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. J Steroid Biochem Mol Biol 2004;89-90:539-543.
39. Dunlap N, Schwartz GG, Eads D, Cramer SD, Sherk AB, John V, Koumenis C: 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2) potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 2003;89:746-753.
40. Posner G, Lee J, Wang Q, Peleg S, Burke M, Brem H, Dolan P, Kensler T: Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha,25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem 1998;41:3008-3014.
41. Kensler T, Dolan P, Gange S, Lee J, Wang Q, Posner G: Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. Carcinogenesis 2000;21:1341-1345.
42. Dixon KM, Deo SS, Wong G, Slater M, Norman AW, Bishop JE, Posner GH, Ishizuka S, Halliday GM, Reeve VE, Mason RS: Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol 2005;97:137-143.
43. Reddy CD, Patti R, Guttapalli A, Maris JM, Yanamandra N, Rachamallu A, Sutton LN, Phillips PC, Posner GH: Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. J Cell Biochem 2006;97:198-206.
44. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-1051.
45. Suit HD, Sedlacek RS, Silver G, Dosoretz D: Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation. Radiat Res 1985;104:47-65.
46. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW: Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983;80:5573-5577.
47. Dawson RMC, Elliott DC, Elliott WH, Jones KM: Data for Biochemical Research, ed 3. New York, Oxford University Press, 1986.
48. Kandel ES, Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 1999;253:210-229.
49. Lewis TS, Shaprio PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
50. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183.
51. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
52. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-1291.
53. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.